MAIA Biotechnology Files 8-K: Material Agreement, Equity Sales

Ticker: MAIA · Form: 8-K · Filed: May 28, 2025 · CIK: 1878313

Sentiment: neutral

Topics: material-agreement, equity-sale, 8-k

TL;DR

MAIA Bio inked a deal & sold stock, filing 8-K today.

AI Summary

On May 27, 2025, MAIA Biotechnology, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and other events. The filing was made on May 28, 2025.

Why It Matters

This 8-K filing indicates significant corporate activity for MAIA Biotechnology, including a new material agreement and equity transactions, which could impact its financial standing and future operations.

Risk Assessment

Risk Level: medium — The filing details a material definitive agreement and unregistered sales of equity securities, which can introduce financial and operational risks.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by MAIA Biotechnology, Inc.?

The filing states that MAIA Biotechnology, Inc. entered into a material definitive agreement on May 27, 2025, but the specific details of this agreement are not provided in the excerpt.

What type of events are reported in this 8-K filing?

This 8-K filing reports on the entry into a material definitive agreement, unregistered sales of equity securities, and other events.

When was this 8-K report filed with the SEC?

This 8-K report was filed with the SEC on May 28, 2025.

What is MAIA Biotechnology, Inc.'s state of incorporation and fiscal year end?

MAIA Biotechnology, Inc. is incorporated in Delaware and its fiscal year ends on December 31.

What is the principal executive office address for MAIA Biotechnology, Inc.?

The principal executive offices of MAIA Biotechnology, Inc. are located at 444 West Lake Street, Suite 1700, Chicago, IL 60606.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 28, 2025 regarding MAIA Biotechnology, Inc. (MAIA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing